SOPHiA GENETICS, a global company focused on artificial intelligence–driven precision medicine, and The University of Texas MD Anderson Cancer Center announced a strategic collaboration aimed at advancing data-driven cancer care. The partnership brings together SOPHiA GENETICS’ AI-based analytical capabilities with MD Anderson’s clinical and research expertise to improve how complex diagnostic data is analyzed and applied in real-world oncology care.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Through the collaboration, the two organizations will launch multiple research and development initiatives and work together to create an advanced next-generation sequencing oncology test. The test will be built using the AI algorithms of the SOPHiA DDM Platform and is designed to transform complex multimodal data into clinically useful insights more efficiently and at greater scale. Researchers at MD Anderson will leverage SOPHiA GENETICS’ technology to develop bioinformatics pipelines that help clinicians interpret complex RNA sequencing data more quickly to support cancer diagnosis and treatment decisions.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said cancer research is entering an era where vast amounts of molecular data are available. She explained that the collaboration reflects the laboratory’s commitment to adopting advanced analytics and artificial intelligence to better understand complex biological information. According to Hansel, this approach will strengthen the ability to convert high-dimensional data into insights that support both research progress and precision oncology.
Beyond test development, SOPHiA GENETICS and MD Anderson will also collaborate on a range of research programs focused on understanding tumor evolution in real time, improving the consistency and reliability of complex genomic testing, and enhancing the process of identifying suitable clinical trials and research pathways for individual patients. This work is intended to support next-generation scientific discovery and provide clinicians with deeper insight into the changing biology of cancer. The collaborative efforts at MD Anderson will be led by Shashikant Kulkarni, Ph.D., Deputy Division Head for Molecular Pathology, and J. Bryan, M.D., Assistant Professor, both within the Division of Pathology and Laboratory Medicine.
Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer at SOPHiA GENETICS, said the collaboration reflects a shared goal of expanding what is possible in cancer research and precision medicine. He noted that by using the SOPHiA DDM Platform as a common analytical foundation, the teams aim to accelerate scientific discovery, support advances in precision oncology, and ensure that innovative technologies can reach patients worldwide quickly and at scale.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
